Targeting public neoantigens for cancer immunotherapy

Alexander H. Pearlman; Michael S. Hwang; Maximilian F. Konig; Emily Han Chung Hsiue; Jacqueline Douglass; Sarah R. DiNapoli; Brian J. Mog; Chetan Bettegowda; Drew M. Pardoll; Sandra B. Gabelli; Nicholas Papadopoulos; Kenneth W. Kinzler; Bert Vogelstein; Shibin Zhou

doi:10.1038/s43018-021-00210-y

Targeting public neoantigens for cancer immunotherapy

Alexander H. Pearlman, Michael S. Hwang, Maximilian F. Konig, Emily Han Chung Hsiue, Jacqueline Douglass, Sarah R. DiNapoli, Brian J. Mog, Chetan Bettegowda, Drew M. Pardoll, Sandra B. Gabelli, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou

Research output: Contribution to journal › Review article › peer-review

Abstract

Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them.

Original language	English (US)
Pages (from-to)	487-497
Number of pages	11
Journal	Nature Cancer
Volume	2
Issue number	5
DOIs	https://doi.org/10.1038/s43018-021-00210-y
State	Published - May 2021

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s43018-021-00210-y

Cite this

@article{1234fa6e520d4fe1ba5494e88110c323,

title = "Targeting public neoantigens for cancer immunotherapy",

abstract = "Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients{\textquoteright} tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them.",

author = "Pearlman, {Alexander H.} and Hwang, {Michael S.} and Konig, {Maximilian F.} and Hsiue, {Emily Han Chung} and Jacqueline Douglass and DiNapoli, {Sarah R.} and Mog, {Brian J.} and Chetan Bettegowda and Pardoll, {Drew M.} and Gabelli, {Sandra B.} and Nicholas Papadopoulos and Kinzler, {Kenneth W.} and Bert Vogelstein and Shibin Zhou",

note = "Publisher Copyright: {\textcopyright} 2021, Springer Nature America, Inc.",

year = "2021",

month = may,

doi = "10.1038/s43018-021-00210-y",

language = "English (US)",

volume = "2",

pages = "487--497",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "5",

}

TY - JOUR

T1 - Targeting public neoantigens for cancer immunotherapy

AU - Pearlman, Alexander H.

AU - Hwang, Michael S.

AU - Konig, Maximilian F.

AU - Hsiue, Emily Han Chung

AU - Douglass, Jacqueline

AU - DiNapoli, Sarah R.

AU - Mog, Brian J.

AU - Bettegowda, Chetan

AU - Pardoll, Drew M.

AU - Gabelli, Sandra B.

AU - Papadopoulos, Nicholas

AU - Kinzler, Kenneth W.

AU - Vogelstein, Bert

AU - Zhou, Shibin

PY - 2021/5

Y1 - 2021/5

N2 - Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them.

AB - Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them.

UR - http://www.scopus.com/inward/record.url?scp=85106298558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106298558&partnerID=8YFLogxK

U2 - 10.1038/s43018-021-00210-y

DO - 10.1038/s43018-021-00210-y

M3 - Review article

C2 - 34676374

AN - SCOPUS:85106298558

SN - 2662-1347

VL - 2

SP - 487

EP - 497

JO - Nature Cancer

JF - Nature Cancer

IS - 5

ER -

Targeting public neoantigens for cancer immunotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this